Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary in South Africa, Mylan (Proprietary) Limited, has launched a comprehensive portfolio of antiretroviral (ARV) products. South Africa has the world's largest HIV/AIDS population, with approximately 5.6 million1 people living with the disease and an estimated 1.7 million2 people receiving treatment.
Mylan's South African ARV portfolio initially will consist of 11 first- and second-line adult and pediatric regimens. Included are several innovative products, such as fixed-dose combinations, single blister "co-packs," heat-stable products and novel pediatric formulations that have been approved by the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO).
Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's 7 billion people with access to high quality medicine. Recently, Mylan was awarded a 19% share of the ARV tender conducted by the South African government and we already have begun to deliver on this commitment. Building on this, today we are pleased to launch a broad and innovative ARV portfolio for the private sector. We believe that Mylan can set a new standard in the treatment of HIV/AIDS in South Africa by providing health care providers and those living with the disease access to high quality, affordable medicines."